Clinical trial NCT02329925: The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
Official title: The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2015-01-01
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. Tongue Stabilizing Device (TSD) is a preformed appliance for Obstructive Sleep Apnea (OSA) that protrudes the tongue and improves upper airway structure and function during sleep. Investigators will attempt to assess efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing routes in OSA patients during sleep.

Detailed description: Purpose:

The purpose of this study is to determine the efficacy of TSD and to assess if it alters swallowing frequency and breathing modes in OSA patients during sleep.

Hypothesis:

Investigators hypothesize that TSD therapy will improve OSA symptoms and will lead to effective nasal breathing which may decrease swallowing frequency in OSA patients during sleep.

Justification:

The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. OSA occurs when there is complete or partial obstruction in the pharynx during sleep which results in an impact on both breathing and swallowing. Continuous Positive Airway Pressure (CPAP) and Oral Appliance (OA) therapy improve breathing in OSA patients, but these therapies have some disadvantages such as poor adherence and expensiveness. TSD is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep. TSD is simpler and more economical than other therapies and may bring similar benefits. In regards to swallowing, it has been reported that swallowing frequency during sleep increases with OSA severity and when preceded by oronasal breathing. However, it still remains to be determined if the treatment of OSA alters breathing modes and swallowing frequency in OSA patients during sleep. An evaluation of the efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing route may be an important step in the sleep medical field so as to understand the mechanism(s) by which TSD therapy improves the clinical condition of OSA.

Objectives:

The objective of this study is to clarify the mechanism(s) by which TSD therapy improves the clinical condition of OSA in terms of regulation of swallowing and breathing modes in OSA patients during sleep.

Research Methods:

Investigators plan to collect data from a minimum of 60 patients who have been diagnosed with OSA .In addition to the regular sleep study electrodes and measurements, investigators will require four supplementary standard sleep channels that utilize standard sleep recording tools. Breathing modes (pure nasal, oral and oro-nasal) will be evaluated with a nasal pressure transducer, which is traditionally used for patients' evaluation (Braebon) and an additional standard oral flow thermistor sensor (1) (Braebon). The degree of mouth opening will be scored with a jaw sensor® (2). Swallowing will be scored based on a combination of measurements which include laryngeal movements as recorded over the thyroid cartilage with a standard piezoelectric sensor (Opti-Flex, Newlife Technologies, Midlothian, VA, USA) (3), and a sub-mental(SupraHyoid) EMG used for the muscle activity of swallowing (4). Standard polysomnography (PSG) data will be analyzed manually according to AASM criteria by sleep technologists. After regular scoring and sleep evaluation, data from results of the sleep study will be transferred to a CD and one of the authors, Kentaro Okuno, will perform further analysis outside of the laboratory. Using the completed data for sleep stages, apnea and hypopnea events, the swallowing events and breathing modes will be assessed visually and scored. Each epoch will then be evaluated for temporal relation between breathing modes and swallowing as well as for degree of mouth opening, apneas, hypopneas, and arousals. The efficacy endpoint is the change in AHI between baseline and TSD. The polysomnographic results will be subjected to paired Student's t-Tests to demonstrate and difference between baseline and TSD.

Eligibility criteria: Inclusion Criteria

Patients included in this study must:

* be 18 years of age or older
* have an objective diagnosis of mild to moderate obstructive sleep apnea (OSA) \[5 ≤ AHI ≤ 50\]; and
* have a Body Mass Index (BMI) ≤ 35

Exclusion Criteria

Patients are excluded in this study who:

* have had previous surgery of the soft palate;
* have neuromuscular disease;
* are taking medications which disturb sleep; and/or
* have ≤ 90% oxygen saturation levels for 20% of the night.

Primary outcomes:
measure: Apnea-hypopnea index
timeFrame: At baseline
measure: Apnea-hypopnea index
timeFrame: At 2-6 months of TSD treatment follow up
measure: Frequency of swallowing
timeFrame: At baseline
measure: Frequency of swallowing
timeFrame: At 2-6 months of TSD treatment follow up
Secondary outcomes:
measure: Functional Outcomes of Sleep Questionnaire (FOSQ) responses
timeFrame: At baseline
measure: Functional Outcomes of Sleep Questionnaire (FOSQ) responses
timeFrame: At 2-6 months of TSD treatment follow up
measure: Epworth Sleepiness Scale (ESS) questionnaire responses.
timeFrame: At baseline
measure: Epworth Sleepiness Scale (ESS) questionnaire responses.
timeFrame: At 2-6 months of TSD treatment follow up
measure: VR-36 survey responses
timeFrame: At baseline
measure: VR-36 survey responses
timeFrame: At 2-6 months of TSD treatment follow up
measure: Breathing route
timeFrame: At baseline
measure: Breathing route
timeFrame: At 2-6 months of TSD treatment follow up
measure: Swallowing apnea time
timeFrame: At baseline
measure: Swallowing apnea time
timeFrame: At 2-6 months of TSD treatment follow up
measure: Compliance (Measuring adherence (hours/nights and nights/week of intervention use))
timeFrame: At 2-6 months of TSD treatment follow up
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: University of British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Fernanda R Almeida, DDS, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Alshhrani WM, Hamoda MM, Okuno K, Kohzuka Y, Fleetham JA, Ayas NT, Comey R, Almeida FR. The efficacy of a titrated tongue-stabilizing device on obstructive sleep apnea: a quasi-experimental study. J Clin Sleep Med. 2021 Aug 1;17(8):1607-1618. doi: 10.5664/jcsm.9260.